The gradually evolving models have also been tailored to cancer biology, e.g. in non-small cell lung (NSCLC) and breast cancer, where alterations that can be targeted with systemic anti-cancer drugs (epidermal growth factor receptor (EGFR) mutations etc.)influence assignment to one of three or four prognostic strata, depending on the score used in clinical practice. This evidence concerns the gene EGFR and breast cancer.